National Association for Proton Therapy expresses support for CMS rule to improve prior authorization

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.

March 28, 2025

Vol.51 No.12

By Claire Marie Porter and Jacquelyn Cobb

In Brief

Irini Yacoub joins New York Proton Center

Irini Yacoub, a radiation oncologist specializing in head-and-neck and central nervous system cancers, will join the New York Proton Center as a physician.

August 09, 2024

Vol.50 No.32

Clinical Roundup

New payment code and Medicare payment implemented for AI cancer imaging device

Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.

July 26, 2024

Vol.50 No.30

Health Equity

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

The Centers for Medicare and Medicaid Services said it intends to start providing additional reimbursement for some high-cost drugs for people with Medicare who receive care at Indian Health Service or tribal hospitals, beginning Jan. 1, 2025.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

Judiciary News Analysis

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

National Association for Proton Therapy expresses support for CMS rule to improve prior authorization

YOU MAY BE INTERESTED IN

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Irini Yacoub joins New York Proton Center

New payment code and Medicare payment implemented for AI cancer imaging device

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

Renew today!

Subscriber content

National Association for Proton Therapy expresses support for CMS rule to improve prior authorization

YOU MAY BE INTERESTED IN

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Irini Yacoub joins New York Proton Center

New payment code and Medicare payment implemented for AI cancer imaging device

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology